Stockreport

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today p [Read more]